Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

RegulatoryTavneosNegative

AI Analysis

Summary

Amgen's rare disease drug Tavneos faces regulatory challenges after a pivotal supporting study was retracted by a top medical journal, adding to FDA concerns since January. The broader biotech sector showed positive sentiment at BIO 2026 with increased dealmaking activity and FDA regulatory changes.

Outcome Details

Pivotal study retracted by medical journal; drug under FDA scrutiny since January

Importance:7/10

Sentiment:

-0.60

FDA scrutinystudy retractionrare diseaseregulatory riskdealmaking

Related Companies

$AMGN

Read the original article

Published by BioSpace on July 1, 2026 10:40 AM

Read Original